论文部分内容阅读
目的：探讨米索前列醇用于足月妊娠引产的可行性及对母儿的安全性。方法：对８４例足月妊娠单胎头位初产妇，用米索前列醇口服０．１ｍｇ每小时一次，直至胎儿娩出，进行引产（米索组）。以５０例同样条件的孕妇，用催产素引产（催产素组）为对照。结果：米索组及对照组引产成功及有效率分别为９７．６％和８０．０％，Ｐ＜０．０１，有显著性差异。两组１２小时分娩成功率分别为７３．８％与４６．０％，Ｐ＜０．０１，有显著性差异。两组失败率分别为２．４％和２０．０％，Ｐ＜０．０１，有显著性差异。结论：米索前列醇口服用于足月妊娠引产疗效显著、安全、方便，有推广价值
Objective: To investigate the feasibility of misoprostol for induction of labor in full-term pregnancy and the safety of mother and child. Methods: Eighty-four primiparous single-head mothers with full-term pregnancy were treated with misoprostol orally at 0.1 mg once per hour until the fetus was delivered for induction of labor (misoprostol). 50 cases of pregnant women with the same conditions, with oxytocin induction (oxytocin group) as a control. Results: The success rate and effective rate of misoprostol and control group were 97.6% and 80.0%, respectively, P <0.01, with significant difference. The 12-hour delivery rates of two groups were 73.8% and 46.0%, respectively, P <0.01, with significant difference. The failure rates of the two groups were 2.4% and 20.0%, respectively, P <0.01, with significant differences. Conclusion: Misoprostol is effective in term labor induced abortion, which is safe, convenient and worth promoting